Dedicated to Conquering Heart Failure

A clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases

Acute Myocarditis

Cardiol has received IND authorization from the U.S FDA to conduct a Phase II multi-national trial designed to evaluate the efficacy and safety of CardiolRx™ in acute myocarditis – an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people less than 35 years of age.

Learn More

Recurrent Pericarditis

Cardiol has received IND authorization from the U.S. FDA to conduct a Phase II open-label pilot study designed to evaluate the tolerance, safety, and disease endpoints of CardiolRx™ in patients with recurrent pericarditis –  the most common of pericardial diseases with symptoms that include debilitating chest pain, shortness of breath, and fatigue.

Learn More

Viral Infection and CVD

CardiolRx™ is currently being evaluated in a Phase II/III multi-national study, the LANCER trial, to evaluate its safety and efficacy as a cardioprotective therapy to reduce major cardiorespiratory events and improve symptoms in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, CVD, and to investigate the impact of CardiolRx™ on key cardiac and inflammatory biomarkers.

Learn More

Heart Failure

Cardiol is developing a subcutaneous cannabidiol formulation targeting the inflammation and fibrosis associated with the development and progression of heart failure – a chronic condition estimated to affect 64 million globally and is a leading cause of death and hospitalization, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.

Learn More


All News